Cannabinoid physiology and pharmacology: 30 Years of progress

Neuropharmacology

Volumn 47, Issue SUPPL. 1, 2004, Pages 345-358

  Howlett, Allyn C ^a,c   Breivogel, Christopher S ^b   Childers, Steven R ^c   Deadwyler, Samuel A ^c   Hampson, Robert E ^c   Porrino, Linda J ^c  

^a Neurosci of Drug Abuse Res Program   (United States)

^b Campbell University   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

2 Arachidonoylglycerol; Adenylyl cyclase; Anandamide; Antinociception; Basal ganglia; Cognition; CP55940; Depolarization induced suppression of inhibition (DSI); Dronabinol; Endocannabinoid; G protein coupled receptors; Hippocampus; Limbic system; Memory

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; ANTINOCICEPTIVE AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CYCLIC AMP; DRONABINOL; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LEVONANTRADOL; MITOGEN ACTIVATED PROTEIN KINASE; PALMITOYLETHANOMIDE; RIMONABANT; UNCLASSIFIED DRUG;

AUTORADIOGRAPHY; BASAL GANGLION; BRAIN METABOLISM; CALCIUM CONDUCTANCE; CEREBELLUM; CLINICAL TRIAL; ENZYME ACTIVITY; HIPPOCAMPUS; HUMAN; IN SITU HYBRIDIZATION; LIGAND BINDING; NEUROIMAGING; NONHUMAN; POSTSYNAPTIC INHIBITION; POTASSIUM CONDUCTANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; TISSUE DISTRIBUTION;

EID: 4644331847     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.07.030     Document Type: Article

References (156)

1. Abood M.E., Martin B.R. Neurobiology of marijuana abuse. Trends Pharmacol. Sci. 13:1992;201-206
2. 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol. Biochem. Behav. 46:1993;575-579
3. Adams I.B., Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 91:1996;1585-1614
4. 1- tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 38:1986;21-43
5. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. 68:2002;247-286
6. Alger B.E., Pitler T.A., Wagner J.J., Martin L.A., Morishita W., Kirov S.A., Lenz R.A. Retrograde signalling in depolarization-induced suppression of inhibition in rat hippocampal CA1 cells. J. Physiol. 496:1996;197-209
7. Barth F., Rinaldi-Carmona M. The development of cannabinoid antagonists. Curr. Med. Chem. 6:1999;745-755
8. Bayewitch M., Avidor-Reiss T., Levy R., Barg J., Mechoulam R., Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 375:1995;143-147
9. Beau F.E., Alger B.E. Transient suppression of GABA-A-receptor-mediated IPSPs after epileptiform burst discharges in CB1 pyramidal cells. J. Neurophysiol. 79:1998;659-669
10. Bidaut-Russell M., Devane W.A., Howlett A.C. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J. Neurochem. 55:1990;21-26
11. Biegon A., Kerman I.A. Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. Neuroimage. 14:2001;1463-1468
12. Black S.C. Cannabinoid receptor antagonists and obesity. Curr. Opin. Investig. Drugs. 5:2004;389-394
13. Bloom A.S., Tershner S., Fuller S.A., Stein E.A. Cannabinoid-induced alterations in regional cerebral blood flow in the rat. Pharmacol. Biochem. Behav. 57:1997;625-631
14. Bornheim L.M., Correia M.A. Effect of cannabidiol on cytochrome P-450 isozymes. Biochem. Pharmacol. 38:1989;2789-2794
15. Bornheim L.M., Kim K.Y., Chen B., Correia M.A. The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism. Biochem. Biophys. Res. Commun. 197:1993;740-746
16. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312:1995;637-641
17. Bouaboula M., Poinot-Chazel C., Marchand J., Canat X., Bourrie B., Rinaldi-Carmona M., Calandra B., Le Fur G., Casellas P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237:1996;704-711
18. Breivogel C.S., Sim L.J., Childers S.R. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther. 282:1997;1632-1642
19. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem. 273:1998;16865-16873
20. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J. Neurochem. 73:1999;2447-2459
21. Breivogel C.S., Griffin G., Di M.V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60:2001;155-163
22. Burkey T.H., Quock R.M., Consroe P., Ehlert F.J., Hosohata Y., Roeske W.R., Yamamura H.I. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur. J. Pharmacol. 336:1997a;295-298
23. trahydrocannabinol is a partial agonist of can nabinoid receptors in mouse brain. Eur. J. Pharmacol. 323:1997b;R3-R4
24. Burstein S.H., Audette C.A., Charalambous A., Doyle S.A., Guo Y., Hunter S.A., Makriyannis A. Detection of cannabinoid receptors by photoaffinity labelling. Biochem. Biophys. Res. Commun. 176:1991;492-497
25. Burstein S., Budrow J., Debatis M., Hunter S.A., Subramanian A. Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem. Pharmacol. 48:1994;1253-1264
26. Buzsaki G. Memory consolidation during sleep: a neurophysiological perspective. J. Sleep Res. 7:(1):1998;17-23
27. Cabral G.A., Dove Pettit D.A. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J. Neuroimmunol. 83:1998;116-123
28. Cadas H., Gaillet S., Beltramo M., Venance L., Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16:1996;3934-3942
29. Calignano A., La Rana G., Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol. 419:2001;191-198
30. Carlson G., Wang Y., Alger B.E. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat. Neurosci. 5:2002;723-724
31. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106:1992;231-232
32. Childers S.R., Pacheco M.A., Bennett B.A., Edwards T.A., Hampson R.E., Mu J., Deadwyler S.A. Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochem. Soc. Symp. 59:1993;27-50
33. Cohen C., Perrault G., Voltz C., Steinberg R., Soubrie P. SR141716, a central cannabinoid (CB) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav. Pharmacol. 13:2002;451-463
34. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 263:1992;1118-1126
35. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., Martin B.R. Cannabinoid structure-ctivity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 265:1993;218-226
36. Consroe P., Mechoulam R. Anticonvulsant and neurotoxic effects of tetrahydrocannabinol stereoisomers. NIDA Res. Monogr. 79:1987;59-66
37. Csicsvari J., Hirase H., Mamiya A., Buzsaki G. Ensemble patterns of hippocampal CA3-CA1 neurons during sharp wave-associated population events. Neuron. 28:2000;585-594
38. 2+ influx at parallel fibre synapses of the rat cerebellum. J. Physiol. 557:2004;159-174
39. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., Vanderschuren L.J., Schoffelmeer A.N. A cannabinoid mechanism in relapse to cocaine seeking. Nat. Med. 7:2001;1151-1154
40. De Vries T.J., Homberg J.R., Binnekade R., Raaso H., Schoffelmeer A.N. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berlin). 168:2003;164-169
41. Deadwyler S.A., Hampson R.E. Differential but complementary mnemonic functions of the hippocampus and subiculum. Neuron. 42:2004;465-476
42. Deadwyler S.A., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptors Channels. 1:1993;121-134
43. Deadwyler S.A., Heyser C.J., Hampson R.E. Complete adaptation to the memory disruptive effects of delta-9-THC following 35 days of exposure. Neurosci. Res. Commun. 17:1995;9-18
44. Devane W.A., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613
45. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949
46. Dewey W.L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-178
47. Dill J.A., Howlett A.C. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J. Pharmacol. Exp. Ther. 244:1988;1157-1163
48. DiMarzo V., Bisogno T., De Petrocellis L., Melck D., Martin B.R. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Curr. Med. Chem. 6:1999;721-744
49. DiMarzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75:2000;2434-2444
50. Duarte C., Alonso R., Bichet N., Cohen C., Soubrie P., Thiebot M.H. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior. Neuropsychopharmacology. 29:2004;911-920
51. Egertova M., Elphick M.R. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J. Comp Neurol. 422:2000;159-171
52. Egertova M., Giang D.K., Cravatt B.F., Elphick M.R. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc. R. Soc. Lond B Biol. Sci. 265:1998;2081-2085
53. Fan F., Tao Q., Abood M., Martin B.R. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res. 706:1996;13-20
54. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48:1995;443-450
55. Fernandez J.R., Allison D.B. Rimonabant Sanofi-Synthelabo. Curr. Opin. Investig. Drugs. 5:2004;430-435
56. 9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse. 45:2002;134-142
57. 14C]deoxyglucose study. Brain Res. 962:2003;169-179
58. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83:2003;1017-1066
59. Giuffrida A., Beltramo M., Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther. 298:2001;7-14
60. Glass M., Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17:1997;5327-5333
61. Glass M., Dragunow M., Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 77:1997;299-318
62. 9- Tetrahydrocannabinol alters flow of blood to subcortical areas of the conscious rat brain. Life Sci. 17:1975;477-482
63. Hampson R.E., Simeral J.D., Deadwyler S.A. Distribution of spatial and nonspatial information in dorsal hippocampus. Nature. 402:1999;610-614
64. Hampson R.E., Simeral J.D., Deadwyler S.A. What ensemble recordings reveal about functional hippocampal cell encoding. Prog. Brain Res. 130:2001;345-357
65. Hampson R.E., Simeral J.D., Deadwyler S.A. "Keeping on track": firing of hippocampal neurons during delayed-nonmatch-to-sample performance. J. Neurosci. 22:2002;RC198
66. Hampson R.E., Zhuang S.Y., Weiner J.L., Deadwyler S.A. Functional significance of cannabinoid-mediated, depolarization-induced suppression of inhibition (DSI) in the hippocampus. J. Neurophysiol. 90:2003;55-64
67. Henry D.J., Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci. Lett. 186:1995;91-94
68. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583
69. Hollister L.E. Health aspects of cannabis. Pharmacol. Rev. 38:1986;1-20
70. Houston D.B., Howlett A.C. Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol. Pharmacol. 43:1993;17-22
71. Howlett A.C. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci. 35:1984;1803-1810
72. Howlett A.C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol. Pharmacol. 27:1985;429-436
73. Howlett A.C. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 68-9:2002;619-631
74. Howlett A.C., Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26:1984;532-538
75. Howlett A.C., Qualy J.M., Khachatrian L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29:1986;307-313
76. 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology. 29:1990;161-165
77. Howlett A.C., Berglund B., Melvin L.S. Cannabinoid receptor agonists and antagonists. Curr. Pharm. Des. 1:1995;343-354
78. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54:2002;161-202
79. Huffman J.W. Cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem. 6:1999;705-720
80. Jarai Z., Wagner J.A., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Razdan R.K., Zimmer A., Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA. 96:1999;14136-14141
81. Johnson M.R., Melvin L.S., Althuis T.H., Bindra J.S., Harbert C.A., Milne G.M., Weissman A. Selective and potent analgetics derived from cannabinoids. J. Clin. Pharmacol. 21:1981;271S-282S
82. Katona I., Sperlagh B., Sik A., Kafalvi A., Vizi E.S., Mackie K., Freund T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19:1999;4544-4558
83. Katona I., Rancz E.A., Acsady L., Ledent C., Mackie K., Hajos N., Freund T.F. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci. 21:2001;9506-9518
84. Kim J., Isokawa M., Ledent C., Alger B.E. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J. Neurosci. 22:2002;10182-10191
85. Kuster J.E., Stevenson J.I., Ward S.J., D'Ambra T.E., Haycock D.A. Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J. Pharmacol. Exp. Ther. 264:1993;1352-1363
86. Lallemand F., Soubrie P.H., De Witte P.H. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcohol Clin. Exp. Res. 25:2001;1317-1323
87. Landsman R.S., Burkey T.H., Consroe P., Roeske W.R., Yamamura H.I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334:1997;R1-R2
88. Lenz R.A., Alger B.E. Calcium dependence of depolarization-induced suppression of inhibition in rat hippocampal CA1 pyramidal neurons. J. Physiol. 521:1999;147-157
89. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3825-3829
90. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503
91. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15:1995;6552-6561
92. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668
93. Maneuf Y.P., Brotchie J.M. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br. J. Pharmacol. 120:1997;1397-1398
94. 9-Tetrahydrocannabinol alters cerebral metabolism in a biphasic, dose-dependent manner in rat brain. Eur. J. Pharmacol. 202:1991;373-378
95. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgansberger W., Di Marzo V., Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 418:2002;530-534
96. Martin B.R. Cellular effects of cannabinoids. Pharmacol. Rev. 38:1986;45-74
97. Martin B.R., Mechoulam R., Razdan R.K. Discovery and characterization of endogenous cannabinoids. Life Sci. 65:1999;573-595
98. Mechoulam R. Marihuana chemistry. Science. 168:1970;1159-1166
99. Mechoulam R., Gaoni Y. The absolute configuration of delta-1- tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett. 12:1967;1109-1111
100. Mechoulam R., Hanus L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res. Manag. 6:2001;67-73
101. Mechoulam R., Braun P., Gaoni Y. A stereospecific synthesis of (-)-delta 1- and (-)-delta 1(6)-tetrahydrocannabinols. J. Am. Chem. Soc. 89:1967;4552-4554
102. Mechoulam R., Ben Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90
103. Moldrich G., Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides. 21:2000;1735-1742
104. Morishita W., Kirov S.A., Alger B.E. Evidence for metabotropic glutamate receptor activation in the induction of depolarization-induced suppression of inhibition in hippocampal CA1. J. Neurosci. 18:1998;4870-4882
105. Mukhopadhyay S., Chapnick B.M., Howlett A.C. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am. J. Physiol. Heart Circ. Physiol. 282:2002;H2046-H2054
106. Offertaler L., Mo F.M., Batkai S., Liu J., Begg M., Razdan R.K., Martin B.R., Bukoski R.D., Kunos G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol. 63:2003;699-705
107. Oviedo A., Glowa J., Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 616:1993;293-302
108. Pacheco M., Childers S.R., Arnold R., Casiano F., Ward S.J. Aminoalkylindoles: actions on specific G-protein-linked receptors. J. Pharmacol. Exp. Ther. 257:1991;170-183
109. Pacheco M.A., Ward S.J., Childers S.R. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res. 603:1993;102-110
110. Pacheco M.A., Ward S.J., Childers S.R. Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes. J. Neurochem. 62:1994;1773-1782
111. Pertwee R.G. The central neuropharmacology of psychotropic cannabinoids. Pharmacol. Ther. 36:1988;189-261
112. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6:1999;635-664
113. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert. Opin. Investig. Drugs. 9:2000;1553-1571
114. Pertwee R.G., Stevenson L.A., Griffin G. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br. J. Pharmacol. 110:1993;1483-1490
115. Pettit D.A., Harrison M.P., Olson J.M., Spencer R.F., Cabral G.A. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J. Neurosci. Res. 51:1998;391-402
116. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4:2003;873-884
117. Pitler T.A., Alger B.E. Depolarization-induced suppression of GABAergic inhibition in rat hippocampal pyramidal cells: G protein involvement in a presynaptic mechanism. Neuron. 13:1994;1447-1455
118. Poncelet M., Maruani J., Calassi R., Soubrie P. Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci. Lett. 343:2003;216-218
119. Pontieri F.E., Conti G., Zocchi A., Fieschi C., Orzi F. Metabolic mapping of the effects of WIN 55212-2 intravenous administration in the rat. Neuropsychopharmacology. 21:1999;773-776
120. Prather P.L., Martin N.A., Breivogel C.S., Childers S.R. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol. Pharmacol. 57:2000;1000-1010
121. Razdan R.K. Structure-ctivity relationships in cannabinoids. Pharmacol. Rev. 38:1986;75-149
122. Reggio P.H., Traore H. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem. Phys. Lipids. 108:2000;15-35
123. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., Le Fur G.L. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244
124. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliere J.C., Le Fur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:1998;644-650
125. 9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol. Biochem. Behav. 40:1991;593-598
126. 9-tetrahydrocannabinol treatment. Pharmacol. Biochem. Behav. 47:1994;33-40
127. 9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 51:1995;731-737
128. 9- tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res. Mol. Brain Res. 46:1997;100-108
129. Schmid H.H. Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem. Phys. Lipids. 108:2000;71-87
130. 35S]thio)triphosphate binding in rat brain membranes. Life Sci. 59:1996;659-668
131. Selley D.E., Sim L.J., Xiao R., Liu Q., Childers S.R. mu-Opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol. Pharmacol. 51:1997;87-96
132. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16:1996;4322-4334
133. 9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride]. Biochem. Pharmacol. 51:1996;669-676
134. 35S]GTPγS autoradiography in rat brain. J. Neurosci. 16:1996a;8057-8066
135. Sim L.J., Selley D.E., Xiao R., Childers S.R. Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum. Eur. J. Pharmacol. 307:1996b;97-105
136. Sim-Selley L.J. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit. Rev. Neurobiol. 15:2004;91-119
137. Sim-Selley L.J., Childers S.R. Neuroanatomical localization of receptor-activated G proteins in brain. Methods Enzymol. 344:2002;42-58
138. Slipetz D.M., O'Neill G.P., Favreau L., Dufresne C., Gallant M., Gareau Y., Guay D., Labelle M., Metters K.M. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol. Pharmacol. 48:1995;352-361
139. Stein E.A., Fuller S.A., Edgemond W.S., Campbell W.B. Selective effects of the endogenous cannabinoid arachidonylethanolamide (anandamide) on regional cerebral blood flow in the rat. Neuropsychopharmacology. 19:1998;481-491
140. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778
141. Sugiura T., Waku K. 2-Arachidonoylglycerol and the cannabinoid receptors. Chem. Phys. Lipids. 108:2000;89-106
142. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97
143. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411
144. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78:1997;43-50
145. van der Stelt M., Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur. J. Pharmacol. 480:2003;133-150
146. Varma N., Carlson G.C., Ledent C., Alger B.E. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 21:2001;RC188
147. Varma N., Brager D., Morishita W., Lenz R.A., London B., Alger B. Presynaptic factors in the regulation of DSI expression in hippocampus. Neuropharmacology. 43:2002;550-562
148. Wagner J.A., Varga K., Jarai Z., Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension. 33:1999;429-434
149. 9-tetrahydrocannabinol administration in the rat. Psychopharmacology (Berlin). 161:2002;129-136
150. Wilson R.S., May E.L. Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J. Med. Chem. 18:1975;700-703
151. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 410:2001;588-592
152. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science. 296:2002;678-682
153. Wilson R.I., Kunos G., Nicoll R.A. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron. 31:2001;453-462
154. Yesavage J.A., Leirer V.O., Denari M., Hollister L.E. Carry-over effects of marijuana intoxication on aircraft pilot performance: a preliminary report. Am. J. Psychiatry. 142:1985;1325-1329
155. Zhuang S.Y., Chen Y., Weiner J.L., Hampson R.E., Deadwyler S.A. Lack of functional presynaptic, but putative postsynaptic actions of cannabinoids in hippocampal neurons. Soc. Neurosci. Abstracts. 29:2003;462
156. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457